Assistant Professor, Medicine, USC School of Medicine
Oncology
Dr. Allen S. Yang, MD
Doctor Allen S. Yang, MD works in the field of Oncology. He attended Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. Allen Yang is also published. He has 35 publications published. The lastest publication: "A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.'
Publications
- Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
- A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
- A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
- A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation.
- Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis.
- Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer.
- Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA.
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
- Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer.
- Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.
- FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16.
- Incorporation of zebularine from its 2'-deoxyribonucleoside triphosphate derivative and activity as a template-coding nucleobase.
- Examination of IGF2 and H19 loss of imprinting in bladder cancer.
- Evaluating new treatment options for MDS.
- Effect of cytarabine and decitabine in combination in human leukemic cell lines.
- Changes in DNA methylation patterns in subjects exposed to low-dose benzene.
- LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.
- Rapid and quantitative method of allele-specific DNA methylation analysis.
- DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
- Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
- Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
- Mitoxantrone: a hypomethylating agent?
- Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
- Identification of preferential target sites for human DNA methyltransferases.
- Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study.
- Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns.
- The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
- 2''-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.
- A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.
- Lack of increases in methylation at three CpG-rich genomic loci in non-mitotic adult tissues during aging.
- Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
- Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm.
- LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
- Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation.
Schools
University of Southern California Keck School of Medicine
Harbor UCLA Med Center
Conditions Treated
- Anemia
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Harbor - UCLA Medical Center -
Keck School of Medicine of USC
Helpful Reviews
Similar Doctors
|
Dr. Gerry C. Bohac, MD |
|
|
Dr. Jeffrey S. Wiezorek, MD |